b'Scan this QR code or visit LONSURFhcp.com to learn more about this combination regimenLONSURF + bevacizumab IMPROVED OVERALL SURVIVAL 1EFFICACY: PRIMARY ENDPOINTMedian OS increased by 3.3 months 1009080 10.8monthsPercentage of patients70 (9.4-11.8) LONSURF + bevacizumab (n=246)60 LONSURF (n=246)50 HR=0.61 ([95% CI: 0.49-0.77]; P0.001)4030 7.520 months10 (6.3-8.6)00 1 23 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20MonthNo. at riskLONSURF + bevacizumab 246 244 239 230 217 203 183 160 149 131 119 104 88 69 52 37 24 13 2 0 0LONSURF 246 242 230 205 184 163 143 120 108 95 85 76 63 44 24 16 10 5 2 1 0Results were consistent across subgroups regardless of age, sex, location of primary disease, number of metastatic sites, RAS mutation status, and prior bevacizumab treatment. 2SUNLIGHT Study Design 1SUNLIGHT was a phase 3, international, randomized, open-label study to evaluate the efficacy and safety of LONSURF used in combination with bevacizumab vs LONSURF alone in patients with previously treated mCRC. The primary endpoint was OS and a secondary endpoint was PFS.3L, third-line; mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression-free survival.SELECTED IMPORTANT SAFETY INFORMATION (contd) USE IN SPECIFIC POPULATIONS (contd)Hepatic Impairment: Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin 1.5 times ULN and any AST) hepatic impairment. Patients with severe hepatic impairment (total bilirubin 3 times ULN and any AST) were not studied. No adjustment to the starting dosage of LONSURF is recommended for patients with mild hepatic impairment.ADVERSE REACTIONSSerious adverse reactions occurred in 25% of patients. The most frequent serious adverse reactions (2%) were intestinal obstruction (2.8%), and COVID-19 (2%). Fatal adverse reactions occurred in 1.2% of patients who received LONSURF in combination with bevacizumab, including rectal fistula (0.4%), bowel perforation (0.4%) and atrial fibrillation (0.4%). Please see brief summary of Prescribing Information on adjacent pages.Taiho_Directory_USMed_Dec2023_FullAd_NAout_7.875x10.75_L09.indd 2 11/27/23 6:17 PM'